Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness,...

Full description

Bibliographic Details
Main Authors: G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò
Format: Article
Language:English
Published: Bioscientifica 2019-05-01
Series:Endocrine Connections
Subjects:
pituitary tumors
aggressive pituitary adenomas
peptide receptor radionuclide therapy
PRRT
Online Access:https://ec.bioscientifica.com/view/journals/ec/8/5/EC-19-0065.xml

Internet

https://ec.bioscientifica.com/view/journals/ec/8/5/EC-19-0065.xml

Similar Items